Isaac Ro is a partner at Catalio Capital Management and a board member at PinkDx, PrognomiQ and Visby Medical. He previously chaired Haystack Oncology, was CFO of Sema4 and Thrive Earlier Detection, led life-sciences equity research at Goldman Sachs and Leerink Partners, and invested in healthcare at Independence Investments.
Isaac Ro is a partner at Catalio Capital Management and a board member at PinkDx, PrognomiQ and Visby Medical. He previously chaired Haystack Oncology, was CFO of Sema4 and Thrive Earlier Detection, led life-sciences equity research at Goldman Sachs and Leerink Partners, and invested in healthcare at Independence Investments.
Career
Isaac Ro holds a BA, History from Middlebury College.
Partner at Catalio Capital Management until PresentPBoard Member at PinkDx until Present
PBoard Member at PrognomiQ until Present
VMBoard Member at Visby Medical until Present
Head of US Medical Technology and Life Science Tools Equity Research at Goldman Sachs from 2010 to 2019